This 2002 European Group for Blood and Marrow Transplantation (EBMT) activity survey concentrates on current status, increase and decrease in haematopoietic stem cell transplantation (HSCT) activity in Europe and investigates the association of transplant rates with team density. In 2002, there were 20 207 HSCT, 6915 allogeneic (34%), 13 292 autologous (66%) and 3947 additional re-or multiple transplants collected from 586 centres in 39 European countries. Main indications were leukaemias (6523 (32%; 76% allogeneic)); lymphomas (10 760 (53%; 92% autologous)); solid tumours (1913 (9%; 92% autologous)) and nonmalignant disorders (874 (4%; 92% allogeneic)). Compared to 2001, there were increases (410%) for AML, ALL 1st CR, CML not 1st cP, MDS, SAA and CLL in allogeneic HSCT and for MDS, Ewing's sarcoma, soft-tissue sarcoma and ovarian cancer in autologous HSCT. Decreases (410%) were observed in autologous HSCT for acute leukaemias beyond 1st CR, CML cP, glioma, breast cancer and lung cancer. Correlation of transplant rates (number of transplants per 10 million inhabitants) with team density (number of transplant teams per 10 million inhabitants) suggests different diffusion patterns for autologous compared to allogeneic HSCT. These data describe current practice for blood and marrow transplantation in Europe and give some hints about mechanisms involved in HSCT rates. Bone Marrow Transplantation (2004Transplantation ( ) 34, 855-875. doi:10.1038 Keywords: haematopoietic stem cell; team density; transplant rates; diffusion of technology Haematopoietic stem cell transplantation (HSCT) has seen a rapid increase and substantial change over the last decade. It is an established therapy for many severe acquired or congenital disorders of the haematopoietic system and for chemosensitive, radiosensitive or immunosensitive malignancies. Haematopoietic stem cells from bone marrow, peripheral blood or cord blood are used as the stem cell source. They are derived for autologous use from the patients themselves. Donors for allogeneic HSCT include HLA-identical siblings, other family members or unrelated volunteers from one of the increasing worldwide donor pools or cord blood banks. [1] [2] [3] [4] There are many reasons for this increase of HSCT in Europe. It is based on increased numbers of HSCT in teams already active in 1990 5 as well as on an increase in transplant teams and an extension of transplant activity to countries with previously none or limited numbers of active transplant teams. Numbers of HSCT did not increase at the same rate for autologous and allogeneic HSCT. They did not increase for all indications alike. 6, 7 Specifically, numbers of autologous HSCT for solid tumours declined after a peak in 1997 almost as rapidly as they had previously increased. They were substituted for by increasing numbers of autologous HSCT for lymphoproliferative disorders. For allogeneic HSCT, there remains a steady increase in transplants for all indications with one major exception. Numbers of transplants for CML have been declining since 1999. 8, 9 Such changes in transplant numbers and transplant rates require explanations and warrant studies to examine the factors bringing about such changes. We had previously described a correlation between team density (number of transplant teams per 10 million inhabitants) and transplant rates (number of transplants per 10 million inhabitants). 10 We made use of the sequential European Group for Blood and Marrow Transplantation EBMT activity surveys to re-examine in more detail the dynamics of the diffusion of HSCT within European countries and the relationship between team density and changes in transplant activity. In parallel, we describe current status and the changes in indication from the preceding year. 
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Patients and methods

Data collection and validation
Data collection is based on the EBMT activity surveys introduced in 1990. 5 All EBMT members and affiliated nonmembers are requested annually to report on a survey sheet the numbers of new patients by indication, stem cell source and donor type. In addition, the form collects additional generic information on the numbers of additional re-or multiple transplants, on the percentage of cord blood HSCT and, since 1999, on the percentage of transplants with reduced-intensity conditioning (RIC HSCT).
The EBMT survey, which was adopted by the General Assembly as a mandatory self-reporting system, forms an integral part of a prospective quality assurance programme (http.//www.EBMT.org). The latter includes revalidation of a computer print-out of entered data by reporting teams, crosschecking with national transplant registries and onsite visits.
Teams
In all, 636 teams in 39 European countries were contacted for the 2002 report, of which 586 reported their numbers. In total, 24 reported to be inactive. This corresponds to a 92% return rate and includes 465 of the 473 active EBMT member teams. A total of 26 teams known by the investigators to have been performing HSCT in 2002 were also contacted, but chose not to reply or for unknown reasons failed to do so, despite several efforts to reach them. No major transplant team in Europe is missing from this list.
Teams contacted are listed in the Appendix in alphabetical order according to country, city and EBMT centre code. We received information that in 2002 no blood or marrow transplants were performed in these European countries: Albania, Andorra, Armenia, Azerbaijaan, Bosnia-Herzegovina, Georgia, Iceland, Liechtenstein, Malta, Moldavia, Monaco, San Marino and the Vatican.
Definitions
Transplants are defined as the infusion of haematopoietic stem cells following a conditioning regimen with the intention of replacing the existing haematopoiesis by injected stem cells. 5 First transplants refer to the first transplantation of haematopoietic cells and full information is collected only for first transplants. Therefore, each patient is counted only once, regardless of the number of transplant procedures, thus preventing multiple reporting.
Additional procedures, such as re-or multiple transplants were collected in total, not specified by disease, to receive an estimate of the absolute number of HSCT procedures performed during the year 2002. Retransplants refer to a situation where recipients receive a second HSCT for relapse or rejection of the graft, multiple transplants refer to a planned programme of sequential HSCT. This is the same for allogeneic and autologous HSCT. Owing to its design, the survey cannot distinguish between retransplants and sequential transplants for preceding autologous or allogeneic HSCT. The criteria for RIC HSCT were not defined but left to the individual institution since no consensus has yet been achieved.
11
Donor lymphocyte infusions were not considered as transplants in this setting, although general information on the number of new patients treated with DLI was collected from all institutions.
Team density, transplant rates and diffusion of technology Transplant rates were defined as the number of HSCT per 10 million inhabitants. They were computed as previously defined for each year, disease indication, donor type and country. For each disease indication transplant rates were assessed for all HSCT and separately for autologous, allogeneic and unrelated HSCT and for RIC allogeneic HSCT, DLI and cord blood HSCT. 10 Transplant rates refer to the number of transplants in a given country compared to its own population. The survey cannot make adjustments for patients who cross borders and receive their HSCT in a foreign country.
Team density was defined as the number of transplant teams per 10 million inhabitants. Team density was calculated concerning teams performing both allogeneic and autologous HSCT and for teams performing autologous HSCT only.
Population data were obtained from the US census office (http://www.census.gov). We measured the diffusion of HSCT technology by comparing transplant rates and team density. Diffusion was defined as the dissemination of a technological innovation in a given social system over a particular period of time according to Roger's characterisation. 12 
Statistical analysis
Different descriptive statistical methods were used to analyse the data. The mean, median and standard deviations of numerical variables were calculated on an Excel spreadsheet. The relationship between team size and total transplants was described with a Lorenz curve and the degree of inequality in the relative distribution was measured with the Gini coefficient. A Lorenz curve is a way of graphically presenting a distribution and the Gini coefficient is a numerical representation of the degree of inequality in a distribution that can be derived directly from the Lorenz curve and measures the area between the 451 line and the Lorenz curve.
Team density and transplant rates were calculated for the years 1995 and 2000 and compared by Pearson's correlation. The significance of the correlation coefficients was tested with a t-test.
In order to analyse the dynamic of the relationship between team density and transplant rates, we used a regression analysis of the type y ¼ ax b , where transplant rate is taken as dependent and 1/team density as independent variable. This nonlinear regression was then transformed to linear in the log/log space with the regression coefficients a and b. The significance of the coefficient in the linear regression representing the change in correlation between team density and transplant rates, hence reflecting diffusion, as tested with a t-test.
Results
Participating teams
Of the 586 teams reporting HSCT in 2002, 331 (57%) did both allogeneic and autologous transplants, 230 (39%) restricted their activity to autologous and eight teams (1%) to allogeneic transplants only. In all, 17 teams (3%) reported not to have performed any transplants in 2002.
There was vast heterogeneity of the transplant teams with regard to size. Of all teams, 25% performed less than 10 HSCT in 2002, 6% (32 teams total) more than 100 HSCT. This unequal distribution and the cumulative proportion of HSCT transplants depending on the cumulative proportion of teams is shown in Figure The distribution of autologous and allogeneic transplants differed for the main indications (Figure 2b ). For the leukaemias, 76% of the transplants were allogeneic and 24% autologous; for the lymphoproliferative disorders 8% were allogeneic and 92% autologous; for the solid tumours 8% were allogeneic and 92% autologous, and for the nonmalignant disorders 92% were allogeneic and 8% autologous. The proportion of allogeneic/autologous HSCT was similar compared to 2001 for all main indications, except for leukaemias. There is a trend towards more allogeneic HSCT (73% in 2001 HSCT (73% in , 76% in 2002 Within the main indications, there were further differences depending on subtype and stage of disease, as listed in Table 1 . For example, there were more allogeneic than autologous transplants for acute lymphoid leukaemias. There were more transplants in 1st complete remission for acute myeloid leukaemia; for acute lymphoid leukaemias, there were more allogeneic transplants at later stages of the disease.
For the 6915 allogeneic first transplants, donors were an HLA-identical sibling for 4143 (60%) of the recipients, other family members for 412 (6%) of the recipients, a syngeneic twin for 53 (1%) of the recipients and an unrelated volunteer donor for 2307 (34%) of the recipients. The proportion of donor type among the allogeneic HSCT was similar compared to 2001, but with a continuing increase of unrelated HSCT from 2064 to 2307. Alternative donors were primarily used for patients with leukaemias or nonmalignant disorders.
Stem cell source in 2002. Of the 13 292 autologous first transplants, 359 (4%) were bone marrow derived, 12 751 (97%) from peripheral blood stem cells or from combined bone marrow and peripheral blood stem cell transplants (Table 1 ). This reflects a further decline in the use of bone marrow for autologous HSCT. The last two groups are summarised in tables and figures as peripheral blood stem cell transplants. Of the 6915 allogeneic first transplants, 38% were bone marrow and 62% were peripheral blood stem cell transplants. In the allogeneic setting, the proportion of peripheral blood as stem cell source varied depending on donor type. The proportion of peripheral blood as stem cell source was 64% for HLA-identical sibling donor transplants, 78% for HSCT from other family members, 66% for twin donors and 54% for unrelated donors. A total of 162 allogeneic HSCT were cord blood transplants in 2002. This corresponds to 2% of all allogeneic transplants.
Changes in indications from 2001 to 2002
There were some changes in indications compared to the year 2001 (Table 2) . A more than 10% increase in allogeneic HSCT was observed for AML, ALL 1st CR, CML not 1st cP, MDS, CLL and SAA and in autologous HSCT for MDS, soft-tissue, sarcoma, Ewing's sarcoma and ovarian cancer. A decrease of over 10% was noted in autologous HSCT for acute leukaemias not in 1st CR, CML cP, breast cancer, lung cancer and glioma. There was no decrease 410% in allogeneic HSCT in any group. The changes in CML are worth noting. There is no longer a decrease in allogeneic HSCT for CML but a change from HSCT in a chronic to a more advanced phase. Also worth noting are a small but significant number of allogeneic HSCTs for patients with solid tumours, specifically renal cell cancer, ovarian cancer, colon cancer and breast cancer. 
Changes in transplant activity 1990-2002
The total numbers of transplants increased from 4 234 HSCT in 1990 to the current numbers as illustrated in Figure 3 . There were similar numbers of autologous and allogeneic HSCT in 1990. 10 Allogeneic HSCT increased at an annual rate of about 10%. Autologous HSCT showed a rapid increase in the early 1990s and then levelled off from 1997 onwards. The numbers of teams performing autologous or allogeneic HSCT showed a similar pattern with a steady accrual of teams performing allogeneic HSCT and a rapid increase in autologous HSCT teams in the early 1990s. As a consequence, numbers of HSCT per team increase slightly at a slow steady pace for allogeneic HSCT but showed a peak in 1997 for autologous HSCT and then declined (Figure 4 ). Increase and decrease were different depending on indication and donor type ( Figure 5 ). There was a steady, steep increase for leukaemias in allogeneic HSCT, interrupted only once in 2000/2001, a slow increase for nonmalignant indications and for lymphoproliferative disorders and a low activity for solid tumours (Figure 5a ). A similar steady, steep increase was observed for lymphoproliferative disorders in autologous HSCT. Leukaemias and solid tumours showed increase and decrease and few HSCTs were performed for nonmalignant diseases (Figure 5b ). Of specific interest is the development in CML, which showed a rapid decline in allogeneic HSCT since the year 2000 and an almost complete disappearance of autologous HSCT for this indication. However, in 2002, numbers of allogeneic HSCT for CML in the advanced phase increased again to the same numbers as observed during the peaks in 1999 (Figure 5c ).
Team density and diffusion of HSCT
In order to understand better the dynamic of transplant numbers and team numbers, as shown in Figures 3 and 4 , we assessed transplant rates and team density (Figures 6  and 7 ) and calculated the correlation between transplant rates and team density in the years 1990, 1995 and 2000 for all countries. While the correlation was significant at a 99.0% confidence level in each year for auto HSCTconfirming a previous finding for the years 2001 10 -the relationship was only significant for allo-HSCT in the year 1900 (data not shown).
The above results suggest that the diffusion of autologous HSCT and the diffusion of allogeneic HSCT did not follow the same pattern. We therefore analysed the dynamics of HSCT with a regression analysis of the type y ¼ ax b . The regression with nine countries showed a good fit for autologous HSCT with a R 2 of 0.8969, which indicates that the diffusion of this technology is strongly driven by team density (Figure 8a ). The regression analysis showed only a marginal correlation (R 2 of 0.1425) for allogeneic HSCT with an explained variance of only 14.25% (Figure 8a) .
The results of the linear regression analysis confirm that they are significant for both technologies (Figure 8b ). This leads to the straightforward conclusion that the growth rate of both auto-and allo-HSCT transplant rate depends linearly on the growth rate of 1/team density. 1 The linear association was loose for allogeneic HSCT with a different pattern of presentation, suggesting that the diffusion is driven by other factors as well.
Discussion
This present analysis of the annual EBMT activity survey from the year 2002 yields some clarifying, but at the same time, surprising results. HSCT is an established therapy in Europe with over 20 000 such interventions annually in all major European countries. 6, 7 Allogeneic HSCTs continue to increase with an annual rise of 5-10%, autologous HSCT plateaued at a high level. This superficially stable picture reveals much more heterogeneity when looked at in more detail. There are some rapid changes within individual indications. Moreover, thanks to an overview covering more than a decade, some mechanisms underlying these changes can be identified.
The most important statement with regard to indications is reflected by the fact that no single subgroup showed a decline in transplant numbers for allogeneic HSCT. A strong increase of more than 10% over the previous year was observed for all leukaemias and aplastic anaemia. Specifically, the decline in transplant rates for CML came to a halt and more transplants are now performed for CML in advanced phase than ever before. 8, 9, [13] [14] [15] Concerning autologous HSCT, more heterogeneity was observed. Some indications showed a strong increase, others a strong decrease. As such, breast cancer is no longer the most frequent indication for an autologous HSCT. [16] [17] [18] Numbers alone do not explain the reasons behind these changes. Numbers, however, leave room for interpretation. These indications with a marked increase in allogeneic HSCT were those considered as accepted indications in the field. 4, 6, 19 The extension might be due to integration of new patient categories, for example, patients at higher age within the context of RIC transplant programmes. 20 There is indeed a continued increase in RIC HSCT and almost one-third of allogeneic HSCTs in the year 2002 were such procedures. 11, 20 The changes in indications and the increases or decreases are more difficult to explain for autologous HSCT. Some increases might reflect situations with established indications, for example, Ewing's sarcoma, [21] [22] [23] some decreases might relate to ending of collaborative group study protocols. [24] [25] [26] [27] [28] Prospective controlled studies are still urgently needed for many of the disease indications. Moreover, despite several studies the situation remains unclear with regard to breast cancer. This ambiguity is illustrated by two recent publications and an editorial in the year 2003. [16] [17] [18] Few indications overall in solid tumours can be regarded as accepted indications outside clinical study protocols.
In this report, we strove for a better understanding of dynamics in the changes of indications for HSCT. We had previously found a clear correlation between team density and transplant rates. 10 We therefore looked at the pattern in diffusion of technology. This process in health-related technology in general is defined as the progress of a technical innovation in a given social system over time and encompasses instruments, equipment, drugs and procedures, as well as organisations supporting the delivery of such care. [29] [30] [31] [32] [33] This process of diffusion takes place in stages and a number of factors can facilitate or slow down this process. Economics are usually one main key factor.
In this analysis, we found a clear correlation between team density and transplant rates. This relationship was highly significant and almost linear in a logarithmic regression for autologous HSCT over the whole observation period of a decade. It was still present, but to a much lesser extent and with a skewed distribution for allogeneic HSCT. In addition, it was more pronounced for the year 1990 than for 2000 (data not shown).
These findings warrant an explanation. There are potential hypotheses to explain these differences. Most likely is that patients with defined and accepted indications, such as in allogeneic HSCT, find their way to the transplant centres independent of numbers of transplant teams. Patients with allogeneic HSCT are treated in higher numbers in the few centres available in a given country or distributed in lower numbers to the many centres. In addition, patients with clear indications for allogeneic HSCT may crossborders to centres nearby and alter the pattern of distribution. There is no way of detecting such crossborder transplants in this activity survey. Such changes across the border might be fewer for autologous HSCT. Furthermore, teams for autologous HSCT might be using their infrastructure for additional indications in autologous HSCT. This is less likely to be carried out for allogeneic HSCT. Alternatively, simple innovations spread faster than complex technologies or innovations must correspond to patients' needs. Specialists in health-care economics are now challenged to provide answers to these open questions.
As usual, the EBMT activity survey gives no results on outcome. These data are published separately and with longer follow-up. It describes current practice of HSCT specialist teams in Europe and provides a basis for healthcare administrators, transplant specialists and patients for their decision-making.
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